AHA shares proposals to lower Medicare drug prices with Congress
In a statement submitted to the Senate Finance Committee for a hearing yesterday on lowering drug prices in Medicare, AHA encouraged Congress to implement policies that would increase generic alternatives and discourage anti-competitive tactics while maintaining incentives to develop innovative new therapies. AHA also called for policies to increase transparency in drug pricing; provide rebates to Medicare when a drug’s average manufacturer or sales price exceeds inflation; better align incentives in the Part D reinsurance program; and protect the 340B Drug Pricing Program.
Related News Articles
Headline
The AHA July 13 commented on proposals by the Office of Management and Budget and other federal agencies to revise the Uniform Grants Regulation governing…
Headline
AHA Board Chair Marc Boom, M.D., took the stage July 13 to introduce AHA award winners and a town hall discussion on navigating the 2026 political…
Perspective
As we move into the second half of 2026 and Congress returns to work in Washington, D.C., next week, lawmakers face a list of difficult issues that demand…
Headline
The AHA provided a statement June 30 to the House Ways and Means Committee in advance of a markup July 1 where the committee will consider legislation that…
Headline
The House Energy and Commerce Subcommittee on Health June 25 held a markup session on bills regarding healthcare price transparency, illicit drugs …
Headline
The Food and Drug Administration June 22 announced multiple actions to help accelerate early- and late-stage drug development. The actions are part of a larger…